| Mutant U2AF1 expression alters hematopoiesis and pre-mRNA splicing in vivo CL Shirai, JN Ley, BS White, S Kim, J Tibbitts, J Shao, M Ndonwi, ... Cancer cell 27 (5), 631-643, 2015 | 323 | 2015 |
| Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers FJ Lowery, S Krishna, R Yossef, NB Parikh, PD Chatani, N Zacharakis, ... Science 375 (6583), 877-884, 2022 | 209 | 2022 |
| U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies MA Smith, GS Choudhary, A Pellagatti, K Choi, LC Bolanos, TD Bhagat, ... Nature cell biology 21 (5), 640-650, 2019 | 188 | 2019 |
| U2AF1 mutations alter sequence specificity of pre-mRNA binding and splicing T Okeyo-Owuor, BS White, R Chatrikhi, DR Mohan, S Kim, M Griffith, ... Leukemia 29 (4), 909-917, 2015 | 139 | 2015 |
| Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome CL Shirai, BS White, M Tripathi, R Tapia, JN Ley, M Ndonwi, S Kim, ... Nature communications 8 (1), 14060, 2017 | 125 | 2017 |
| Antigen experienced T cells from peripheral blood recognize p53 neoantigens P Malekzadeh, R Yossef, G Cafri, BC Paria, FJ Lowery, M Jafferji, ... Clinical Cancer Research 26 (6), 1267-1276, 2020 | 92 | 2020 |
| Keap1 cysteine 288 as a potential target for diallyl trisulfide-induced Nrf2 activation S Kim, HG Lee, SA Park, JK Kundu, YS Keum, YN Cha, HK Na, YJ Surh PloS one 9 (1), e85984, 2014 | 92 | 2014 |
| Breast cancers are immunogenic: immunologic analyses and a phase II pilot clinical trial using mutation-reactive autologous lymphocytes N Zacharakis, LM Huq, SJ Seitter, SP Kim, JJ Gartner, S Sindiri, VK Hill, ... Journal of Clinical Oncology 40 (16), 1741, 2022 | 87 | 2022 |
| Adoptive cellular therapy with autologous tumor-infiltrating lymphocytes and T-cell receptor–engineered T cells targeting common p53 neoantigens in human solid tumors SP Kim, NR Vale, N Zacharakis, S Krishna, Z Yu, B Gasmi, JJ Gartner, ... Cancer immunology research 10 (8), 932-946, 2022 | 65 | 2022 |
| Knockdown of HSPA9 induces TP53-dependent apoptosis in human hematopoietic progenitor cells T Liu, K Krysiak, CL Shirai, S Kim, J Shao, M Ndonwi, MJ Walter PLoS One 12 (2), e0170470, 2017 | 33 | 2017 |
| Identification and Validation of T-cell Receptors Targeting RAS Hotspot Mutations in Human Cancers for Use in Cell-based Immunotherapy N Levin, BC Paria, NR Vale, R Yossef, FJ Lowery, MR Parkhurst, Z Yu, ... Clinical Cancer Research 27 (18), 5084-5095, 2021 | 26 | 2021 |
| Rapid identification and evaluation of neoantigen-reactive T-cell receptors from single cells BC Paria, N Levin, FJ Lowery, A Pasetto, DC Deniger, MR Parkhurst, ... Journal of Immunotherapy 44 (1), 1-8, 2021 | 26 | 2021 |
| Mutant U2AF1-induced alternative splicing of H2afy (macroH2A1) regulates B-lymphopoiesis in mice SP Kim, SN Srivatsan, M Chavez, CL Shirai, BS White, T Ahmed, ... Cell reports 36 (9), 2021 | 13 | 2021 |
| Preclinical activity of splicing modulators in U2AF1 mutant MDS/AML CL Shirai, M Tripathi, JN Ley, M Ndonwi, BS White, R Tapia, B Saez, ... Blood 126 (23), 1653, 2015 | 12 | 2015 |
| Mutant U2AF1 expression alters hematopoiesis and Pre-mRNA splicing in transgenic mice CL Shirai, JN Ley, BS White, J Tibbitts, J Shao, M Ndonwi, S Kim, ... Blood 124 (21), 827, 2014 | 4 | 2014 |
| Abstract B41: Mutant U2AF1 alters hematopoiesis and pre-mRNA splicing in transgenic mice. CL Shirai, JN Ley, B White, J Tibbitts, J Shao, M Ndonwi, S Kim, ... Clinical Cancer Research 21 (17_Supplement), B41-B41, 2015 | | 2015 |
| Mutant U2AF1 Expression Alters Hematopoiesis In Transgenic Mice CL Shirai, J Tibbitts, J Shao, M Ndonwi, JN Ley, S Kim, M Tripathi, ... Blood 122 (21), 99, 2013 | | 2013 |
Frank J. LoweryNCIVerified email at nih.gov
